XML 35 R7.htm IDEA: XBRL DOCUMENT
v3.24.1.u1

Organization | 12 Months Ended
--- | ---
Dec. 31, 2023
Organization [Abstract] |
ORGANIZATION | 1. ORGANIZATION The consolidated financial statements include the financial statements of Aptorum Group Limited (the “Company”) and its subsidiaries. The Company and its subsidiaries are hereinafter collectively referred to as the “Group”. The Company, formerly known as APTUS Holdings Limited and STRIKER ASIA OPPORTUNITIES FUND CORPORATION, is a company incorporated on September 13, 2010 under the laws of the Cayman Islands with limited liability. The Company researches and develops life science and biopharmaceutical products within its wholly-owned subsidiary, Aptorum Therapeutics Limited, formerly known as APTUS Therapeutics Limited (“Aptorum Therapeutics”) and its indirect subsidiary companies (collectively, “Aptorum Therapeutics Group”). Below summarizes the list of the major subsidiaries consolidated as of December 31, 2023:
Name |  | Incorporation date |  | Ownership |  | Place of incorporation |  | Principle activities
Aptorum Therapeutics Limited (“ATL”) |  | June 30, 2016 |  | 100% |  | Cayman Islands |  | Research and development of life science and biopharmaceutical products
APTUS MANAGEMENT LIMITED |  | May 16, 2017 |  | 100% |  | Hong Kong |  | Provision of management services to its holding company and fellow subsidiaries
Aptorum Medical Limited |  | August 28, 2017 |  | 90% |  | Cayman Islands |  | Provision of medical clinic services
Paths Innovations Limited |  | April 15, 2019 |  | 100% |  | Cayman Islands |  | Investment holding company
Paths Diagnostics Pte. Limited |  | June 5, 2019 |  | 75% |  | Singapore |  | Research and development of life science and biopharmaceutical products
Acticule Life Sciences Limited |  | June 30, 2017 |  | 80% |  | Cayman Islands |  | Research and development of life science and biopharmaceutical products
Claves Life Sciences Limited |  | August 2, 2017 |  | 100% |  | Cayman Islands |  | Research and development of life science and biopharmaceutical products
Nativus Life Sciences Limited |  | July 7, 2017 |  | 100% |  | Cayman Islands |  | Research and development of life science and biopharmaceutical products
Videns Incorporation Limited |  | March 2, 2017 |  | 100% |  | Cayman Islands |  | Research and development of life science and biopharmaceutical products
Mios Pharmaceuticals Limited |  | March 6, 2018 |  | 97.93% |  | Cayman Islands |  | Research and development of life science and biopharmaceutical products
mTOR (Hong Kong) Limited |  | November 4, 2016 |  | 90% |  | Hong Kong |  | Research and development of life science and biopharmaceutical products
Scipio Life Sciences Limited |  | July 19, 2017 |  | 97.93% |  | Cayman Islands |  | Research and development of life science and biopharmaceutical products
Signate Life Sciences Limited |  | August 28, 2017 |  | 100% |  | Cayman Islands |  | Research and development of life science and biopharmaceutical products

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480424/946-10-50-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480424/946-10-50-2 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//810/tableOfContent Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//205/tableOfContent + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration